Chimeric Polyamides for GAA Repeat-Targeted FXN Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Friedreich's ataxia, caused by defective frataxin gene expression due to GAA trinucleotide repeats, are limited to surgical interventions and lack a cure, with no effective pharmaceutical options to modulate gene expression and alleviate symptoms.
Innovation Solution
Development of chimeric heterocyclic polyamide compounds that selectively bind to the GAA trinucleotide repeat sequence of the frataxin gene, recruiting regulatory molecules to modulate gene expression and counteract defective frataxin production, thereby reducing disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical interventions are used to treat Friedreich's ataxia, then patient symptoms can be managed, but there is no cure and disease progression continues
Solution Approach 1:
The patent applies preliminary action by using antisense oligonucleotides to preemptively target and neutralize the defective frataxin gene expression before it can cause further disease progression. The oligonucleotides are designed to bind to specific sequences in the frataxin mRNA, preventing its translation into defective frataxin protein, thereby stopping the harmful effects at their source.
2Adaptability or versatility
If no pharmaceutical treatment is available, then current medical options are limited, but gene expression cannot be modulated to alleviate symptoms
Solution Approach 1:
The patent employs an intermediary approach by introducing synthetic oligonucleotide molecules that act as mediators between the defective frataxin gene and the cellular translation machinery. These oligonucleotides specifically bind to frataxin mRNA sequences, blocking the translation process without directly altering the DNA genome, thus providing a reversible and targeted pharmaceutical intervention.
3Quantity of substance
If GAA trinucleotide repeats are present in the frataxin gene, then frataxin expression is reduced, but the repeats themselves cannot be directly removed
Solution Approach 1:
The patent applies the extraction principle by specifically targeting and removing the harmful effect of the GAA repeats indirectly. Instead of attempting to physically remove the repeats from the DNA, the oligonucleotides extract or block the problematic mRNA transcripts that are produced from the repeat-containing gene, thereby reducing frataxin expression issues without complex genome editing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively downregulate defective frataxin expression, potentially alleviating symptoms and reducing the severity and frequency of Friedreich's ataxia symptoms by enhancing binding affinity and selectivity to the target DNA sequence.
Implementation Method 1
chimeric heterocyclic polyamide compounds that selectively bind to the GAA trinucleotide repeat sequence of the frataxin gene
Data Source
AI summary
The present disclosure relates to compounds and methods for modulating the expression of fxn, and treating diseases and conditions in which fxn plays an active role.